Advertisement

Evaluating Response to Metformin/Cisplatin Combination in Cancer Cells via Metabolic Measurement and Clonogenic Survival

  • Sang Hyeok Woo
  • Vlad C. Sandulache
  • Liangpeng Yang
  • Heath D. SkinnerEmail author
Protocol
Part of the Methods in Molecular Biology book series (MIMB, volume 1165)

Abstract

Metformin is a commonly utilized antidiabetic agent, which has been associated with improved clinical outcomes in cancer patients. The precise mechanism of action remains unclear, but preclinical evidence suggests that metformin can sensitize tumor cells to the effects to conventional chemotherapeutic agents and ionizing radiation (IR). In this chapter we describe two assays to investigate the effects of combination of metformin and a chemotherapeutic agent (in this case cisplatin) in head and neck cancer squamous cell carcinoma (HNSCC) cell lines.

Key words

Metformin Head and neck cancer Cisplatin Cytotoxicity Apoptosis Metabolism Reactive oxygen species (ROS) Clonogenic survival 

Reference

  1. 1.
    Franken NA, Rodermond HM, Stap J, Haveman J, van Bree C (2006) Clonogenic assay of cells in vitro. Nat Protoc 1:2315–2319PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2014

Authors and Affiliations

  • Sang Hyeok Woo
    • 1
  • Vlad C. Sandulache
    • 2
  • Liangpeng Yang
    • 3
  • Heath D. Skinner
    • 3
    Email author
  1. 1.Department of Head and Neck SurgeryThe University of Texas M. D. Anderson Cancer CenterHoustonUSA
  2. 2.Bobby R. Alford Department of Otolaryngology—Head and Neck SurgeryBaylor College of MedicineHoustonUSA
  3. 3.Department of Radiation OncologyThe University of Texas M. D. Anderson Cancer CenterHoustonUSA

Personalised recommendations